Clinical Trials Logo

Filter by:
NCT ID: NCT06329518 Not yet recruiting - Sepsis Clinical Trials

Rezafungin PK in Patients on ECMO

Start date: April 2024
Phase: Phase 1
Study type: Interventional

Extracorporeal membrane oxygenation (ECMO) is a form of cardiopulmonary life-support for critically ill patients where blood is extracted from the vascular system and circulated by a mechanical pump while it is oxygenated and reinfused into the patient's circulation. It is well known that critically ill patients may experience alterations in antibiotic pharmacokinetics, and as a result, dosing modifications are generally required. There is a need to understand how ECMO circuits affect the pharmacokinetics and disposition of drugs. This study is designed to assess the pharmacokinetics of the new broad-spectrum echinocandin, Rezafungin, in critically ill patients receiving ECMO

NCT ID: NCT06329492 Enrolling by invitation - Osteoarthritis Clinical Trials

Autologous Alpha-2 Macroglobulin Rich Plasma, Safety and Efficacy in Symptomatic Moderate Knee Osteoarthritis

A2MRP
Start date: January 9, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the effectiveness and safety of autologous alpha-2 macroglobulin rich plasma (A2MRP) injections in the treatment of knee osteoarthritis (OA).

NCT ID: NCT06329453 Recruiting - Multiple Sclerosis Clinical Trials

Intestinal Immunity in Neurologic Disease

Start date: August 2, 2022
Phase:
Study type: Observational

The purpose of this study is to ascertain the functional profiles of the immune cells within the gastrointestinal tract and to determine how these cells contribute to autoimmune and neurologic diseases.

NCT ID: NCT06329427 Completed - Clinical trials for Automated Clinical Documentation

Dragon Ambient eXperience (DAX) Copilot Evaluation

DAX
Start date: June 19, 2023
Phase: N/A
Study type: Interventional

AI solutions like, Dragon Ambient eXperience (DAX) Copilot (Nuance/Microsoft), hold the potential to significantly enhance provider and patient interactions and alleviate pain points that contribute to burn out. Atrium Health was the first healthcare system in the world to pilot Nuance's DAX Copilot intelligence (AI) enabled scribe software, which synthesizes a draft clinic note by "listening" to the conversation between a provider and patient. After 180 days of use by primary care clinicians and advanced practice providers (APPs), along with a control group, the investigators assess provider satisfaction, patient experience, and provider efficiency through qualitative and quantitative methods.

NCT ID: NCT06329414 Recruiting - Multiple Sclerosis Clinical Trials

Acceptability and Feasibility of Transcranial Magnetic Stimulation (TMS) for Depression in Multiple Sclerosis

Start date: January 16, 2024
Phase:
Study type: Observational

The goal of this single-arm, observational pilot study is to learn about the safety, feasibility, preliminary efficacy of TMS for the treatment of depression in people with MS. Participants will receive outpatient TMS treatment over the course of 5-6 weeks. Participants will complete validated questionnaires and exams before, during, and after treatment.

NCT ID: NCT06329401 Recruiting - Clinical trials for Progressive Pulmonary Fibrosis

A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis

Start date: April 3, 2024
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of inhaled pirfenidone (AP01) versus placebo on top of standard of care in participants with PPF over 52 weeks.

NCT ID: NCT06329388 Completed - Child Development Clinical Trials

Evaluating the Effects of an Oral Protein Supplement on Children's Growth Patterns

Start date: January 18, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This single-center, randomized controlled pilot study aims to evaluate the efficacy of TruHeight Growth Protein Shake on improving growth patterns in children aged 4-17 years. Over six months, participants will consume the protein shake daily, five times a week, with outcomes measured in terms of type X collagen concentration in urine, height via a stadiometer, and body composition using an INBODY device.

NCT ID: NCT06329258 Completed - Psoriasis Clinical Trials

Combination of Sotyktu and Enstilar for Plaque Psoriasis

Start date: December 6, 2022
Phase: Phase 4
Study type: Interventional

combination deucravacitinib and enstilar foam

NCT ID: NCT06328777 Recruiting - Systemic Sclerosis Clinical Trials

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Start date: June 2024
Phase: Phase 1/Phase 2
Study type: Interventional

RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis

NCT ID: NCT06328738 Recruiting - Colorectal Cancer Clinical Trials

ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

Start date: May 30, 2024
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and recommended dose of ELVN-002 in combination with trastuzumab in participants with advanced-stage HER2-positive tumors and in combination with trastuzumab, and chemotherapy in participants with advanced-stage HER2-positive colorectal cancer and breast cancer.